Catalog No.
RHF82101
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Monoclonal
Tested applications
IF: 1:50-1:200, WB: 1:500-1:1000
Target
Cell division protein kinase 6, Cyclin-dependent kinase 6, Serine/threonine-protein kinase PLSTIRE, CDKN6, CDK6
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q00534
Applications
IF, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.
Clone ID
R2B73
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer., PMID:40010764
A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors' failure: A review of current and investigational treatment for HR+/Her2- breast cancer., PMID:39433229
Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis., PMID:39373732
Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer., PMID:39218402
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer., PMID:38513188
[Preparation and identification of rabbit anti-cyclin dependent kinase 6 (CDK6) antibodies]., PMID:37515341
Green tea EGCG inhibits naïve CD4+ T cell division and progression in mice: An integration of network pharmacology, molecular docking and experimental validation., PMID:37441168
XTP1 facilitates the growth and development of gastric cancer by activating CDK6., PMID:36819538
Artificial Intelligence Predicted Overall Survival and Classified Mature B-Cell Neoplasms Based on Immuno-Oncology and Immune Checkpoint Panels., PMID:36358737
In silico development and experimental validation of a novel 7-gene signature based on PI3K pathway-related genes in bladder cancer., PMID:35896848
Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma., PMID:35121370
PSMC2 knockdown inhibits the progression of oral squamous cell carcinoma by promoting apoptosis via PI3K/Akt pathway., PMID:34979867
Differential Expression of PD-L1 during Cell Cycle Progression of Head and Neck Squamous Cell Carcinoma., PMID:34884892
SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors., PMID:34481366
Longitudinal change of genetic variations in cetuximab-treated metastatic colorectal cancer., PMID:34315006
CDK inhibitors in cancer therapy, an overview of recent development., PMID:34094661
CDK4/6 Inhibitors in Melanoma: A Comprehensive Review., PMID:34071228
Knockdown of MCM8 inhibits development and progression of bladder cancer in vitro and in vivo., PMID:33931059
Knockdown of TMED3 inhibits cell viability and migration and increases apoptosis in human chordoma cells., PMID:33760171
Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer., PMID:33757987
Knockdown of KNTC1 Inhibits the Proliferation, Migration and Tumorigenesis of Human Bladder Cancer Cells and Induces Apoptosis., PMID:33639055
A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer., PMID:33389550
Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities., PMID:33314017
Metformin as a senostatic drug enhances the anticancer efficacy of CDK4/6 inhibitor in head and neck squamous cell carcinoma., PMID:33116117
Release from cell cycle arrest with Cdk4/6 inhibitors generates highly synchronized cell cycle progression in human cell culture., PMID:33052073
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling., PMID:33046519
Interplay and roles of oxidative stress, toll-like receptor 4 and Nrf2 in trichloroethene-mediated autoimmunity., PMID:33007382
CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner., PMID:32929370
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer., PMID:32694159
Robustaflavone induces G0/G1 cell cycle arrest and apoptosis in human umbilical vein endothelial cells and exhibits anti-angiogenic effects in vivo., PMID:32632123
Emerging therapies in mantle cell lymphoma., PMID:32552760
Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells., PMID:32306906
PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma., PMID:32194860
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer., PMID:32130619
Modulating EGFR-MTORC1-autophagy as a potential therapy for persistent fetal vasculature (PFV) disease., PMID:31462148
Novel Carbazole-Piperazine Hybrid Small Molecule Induces Apoptosis by Targeting BCL-2 and Inhibits Tumor Progression in Lung Adenocarcinoma in Vitro and Xenograft Mice Model., PMID:31450709
Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer., PMID:31444334
A major role of TWEAK/Fn14 axis as a therapeutic target for post-angioplasty restenosis., PMID:31395500
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial., PMID:31351869
Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity., PMID:31250942
Therapeutic innovations in breast cancer., PMID:31151842
UNC93B1 promotes tumoral growth by controlling the secretion level of granulocyte macrophage colony-stimulating factor in human oral cancer., PMID:30935694
Immunotherapy and targeted therapy combinations in metastatic breast cancer., PMID:30842061
Advances of systemic treatment for adult soft-tissue sarcoma., PMID:30173532
miR-29b directly targets activation-induced cytidine deaminase in human B cells and can limit its inappropriate expression in naïve B cells., PMID:30081328
Multipronged activity of combinatorial miR-143 and miR-506 inhibits Lung Cancer cell cycle progression and angiogenesis in vitro., PMID:30002440
Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer., PMID:32913968
CDK4, CDK6, cyclin D1, p16(INK4a) and EGFR expression in glioblastoma with a primitive neuronal component., PMID:29150788
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation., PMID:29101163
p16INK4a Expression in Cervical Lesions Correlates with Histologic Grading - a Tertiary Level Medical Facility Based Retrospective Study., PMID:29072058
For research use only. Not for human or drug use.
